Multiple Sclerosis Center, Department of Neurology The Ohio State University Medical Center 395 West 12th Avenue, 7th floor Columbus, OH 43210, USA.
Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.
The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.
目前多发性硬化症（MS）的治疗领域正在迅速发展。醋酸格拉替雷（GA）因其非免疫抑制作用机制以及优越的长期安全性和持续疗效数据而独具特色。在这篇综述中，我们讨论了 GA 的作用机制。然后，我们回顾了减少复发和减缓残疾的疗效数据以及长期安全性数据。最后，我们讨论了这种独特聚合物在 MS 治疗中的可能未来方向。
